<p>虽然关于 “下一代” 减肥疗法这个术语还存在一些歧义，但有一点是清楚的：与当前一代减肥药物不同，理想的减肥药物在治疗过程中不会导致患者失去肌肉质量。</p>
<p>首家开发出更理想的减肥药物的公司可能会获得可观的利润。目前已经有几家公司在开发候选药物，这些药物可能符合这一标准，因此让我们分别来看看它们，因为它们都值得购买。</p>
<h2>1. 礼来</h2>
<p>作为减肥市场的一员，<strong>礼来</strong>（LLY 0.18%）以其拳头产品 Zepbound 而闻名，该药用于治疗肥胖症。仅在第二季度，Zepbound 的销售额就超过了 12 亿美元。但该公司正在心脏代谢医学领域进行大量的研发活动，尽管有许多下一代候选药物，但其中一种尤为有前途。</p>
<p>目前，礼来正在进行一项第 2 期临床试验，研究其名为 bimagrumab 的抗体是否有助于减肥，无论是单独使用还是与 <strong>诺和诺德</strong> 的药物 semaglutide（常用的商品名为 Ozempic 和 Wegovy）联合使用。具体而言，该试验旨在研究 bimagrumab 是否能在与 semaglutide 治疗期间保护肌肉质量，甚至在患者整体体重下降的情况下，可能会增加肌肉质量。</p>
<p>有理由相信礼来将会找到其期望的有益影响。在之前由第三方研究人员进行的一项研究中，研究了该候选药物对患有 2 型糖尿病和肥胖症的患者的影响，结果令人瞩目。经过 48 周的治疗，患者平均减少了 20.5% 的总脂肪质量，同时增加了 3.6% 的瘦体重，显著减少了腰围，总体体重减轻了 6.5%，还改善了血糖水平。在治疗组和安慰剂组之间，出现副作用的比率以及副作用的强度相当相似。</p>
<p>预计礼来对 bimagrumab 的研究将于 2025 年中期结束。如果结果与其他试验一致，该公司无疑将希望将该项目推进到第 3 期研究，然后进行商业化，假设监管机构批准。</p>
<p>如果最终获得销售批准，它可能不会在面对坚决反对的情况下难以获得市场份额。一种有效清除腹部脂肪并略微促进肌肉生长的减肥药物显然是一种赢家，到目前为止市场上没有其他产品可以媲美。而且，当与礼来大力努力研发其他强化抗肥胖药物的努力相结合时，如果第 2 期结果看起来令人满意，其股价可能会迎来重大推动，这是现在购买该股票的另一个理由。</p>
<h2>2. BioAge Labs</h2>
<p><strong>BioAge Labs</strong>（BIOA 4.94%）仍在努力推出其首个药物，但其主力候选药物可能比当今的减肥药物具有一系列引人注目的优势。该项目名为 azelaprag，也可能帮助患者减肥的同时保留甚至增加其瘦肌肉质量。</p>
<p>目前，azelaprag 正处于第 2 期临床试验阶段，正在测试与礼来和诺和诺德生产的拳头减肥药物的联合使用。其第 1b 期临床试验的结果令人鼓舞。</p>
<p>在一项对 21 名长期卧床的老年人进行的为期 10 天的研究中，只有治疗组中的 11 名患者中有 1 名患者的肌肉质量下降，而安慰剂组中有 10 名患者中有 8 名患者的肌肉质量下降。他们的肌肉尺寸也比接受安慰剂的患者明显保持得更好。特别是，他们的大腿围尺寸平均增加了两倍。</p>
<p>事实上，一些接受 azelaprag 的患者实际上看到其部分肌肉尺寸略微增加。动物模型的临床前数据还表明，该候选药物通过促使一系列有利的代谢变化具有强大的减肥效果，但这些发现需要在人类中得到复制后才值得激动。</p>
<p>BioAge 声称 azelaprag 能够取得这些令人印象深刻的成就，因为它导致的生理效应与体育锻炼的效应重叠。如果这是真的，除非出现重大安全信号，并且假设剩余的临床试验按计划进行，很容易看出它可能正在研发一种成功的药物。基于这一潜力，购买该股票是值得的，只要您目前保持小额投资，并且愿意投资于一个风险极高的未盈利生物技术股票。</p>
<p>但不要让这家生物技术公司漫长的盈利之路使您感到过于沮丧。10 月 1 日，它结束了首次公开发行（IPO）和同时进行的私募股份发行，筹集了超过 2.38 亿美元的总收入。其过去 12 个月的运营费用仅为 5150 万美元，因此即使考虑到不久的将来运行中后期和晚期临床试验的更高成本，它至少还有几年时间不需要筹集更多资金。</p>

礼来

<p>这篇文章讨论了两家有前景的减肥股票：礼来和 BioAge Labs。礼来的 Zepbound 已经产生了显著的销售额，其 bimagrumab 候选药正在进行第二阶段试验，旨在在减肥过程中保持肌肉质量。BioAge Labs 正在开发 azelaprag，该药在保持肌肉的同时促进减肥方面显示出潜力，目前正在进行第二阶段试验。这两家公司在减肥市场上处于增长的位置，使它们的股票对投资者具有吸引力</p>

<p>While there's some ambiguity about the term &#34;next generation&#34; when it comes to weight loss therapies, one thing is clear: Unlike the current generation of weight loss drugs, the ideal weight loss medicines won't cause patients to lose muscle mass while they're being treated.</p>
<div class="lb-trans"><p>虽然关于 “下一代” 减肥疗法这个术语还存在一些歧义，但有一点是清楚的：与当前一代减肥药物不同，理想的减肥药物在治疗过程中不会导致患者失去肌肉质量。</p>
</div><p>The first business to develop one of those more ideal weight loss drugs will likely see a significant windfall. There are already a couple of companies in particular that have candidates in development which might fit that bill, so let's examine each, as they're both worth buying.</p>
<div class="lb-trans"><p>首家开发出更理想的减肥药物的公司可能会获得可观的利润。目前已经有几家公司在开发候选药物，这些药物可能符合这一标准，因此让我们分别来看看它们，因为它们都值得购买。</p>
</div><h2>1. Eli Lilly</h2>
<div class="lb-trans"><h2>1. 礼来</h2>
</div><p>As a player in the weight loss market, <strong>Eli Lilly</strong>(LLY 0.18%) is best known for its blockbuster drug Zepbound, which is indicated to treat obesity. In the second quarter alone, sales of Zepbound were worth more than $1.2 billion. But the company is in the process of doing a lot more research and development (R&amp;D) activity within cardiometabolic medicine, and, though it has many next-generation candidates, one stands out as being especially promising.</p>
<div class="lb-trans"><p>作为减肥市场的一员，<strong>礼来</strong>（LLY 0.18%）以其拳头产品 Zepbound 而闻名，该药用于治疗肥胖症。仅在第二季度，Zepbound 的销售额就超过了 12 亿美元。但该公司正在心脏代谢医学领域进行大量的研发活动，尽管有许多下一代候选药物，但其中一种尤为有前途。</p>
</div><p>Lilly is currently doing a phase 2 clinical trial investigating whether its antibody called bimagrumab is helpful for weight loss, either when used alone, or when used in conjunction with <strong>Novo Nordisk</strong>'s drug semaglutide, which is commonly known by the trade names Ozempic and Wegovy. Specifically, the trial is looking at whether bimagrumab is capable of protecting muscle mass during treatment with semaglutide, or potentially even increasing it despite the patient's weight falling overall.</p>
<div class="lb-trans"><p>目前，礼来正在进行一项第 2 期临床试验，研究其名为 bimagrumab 的抗体是否有助于减肥，无论是单独使用还是与 <strong>诺和诺德</strong> 的药物 semaglutide（常用的商品名为 Ozempic 和 Wegovy）联合使用。具体而言，该试验旨在研究 bimagrumab 是否能在与 semaglutide 治疗期间保护肌肉质量，甚至在患者整体体重下降的情况下，可能会增加肌肉质量。</p>
</div><p>There's reason to believe that Lilly will find the beneficial impacts it's looking for here. In a prior phase 2 study conducted by third-party researchers investigating the effects of the candidate on patients with both type 2 diabetes and obesity, the results were phenomenal. After 48 weeks of treatment, patients lost, on average, 20.5% of their total fat mass while actually gaining 3.6% of their lean mass, significantly trimming their waistlines, reducing their total body weight by 6.5%, and improving their blood glucose levels, too. Rates of experiencing side effects, as well as the intensity of side effects, were fairly similar between the treatment and placebo groups.</p>
<div class="lb-trans"><p>有理由相信礼来将会找到其期望的有益影响。在之前由第三方研究人员进行的一项研究中，研究了该候选药物对患有 2 型糖尿病和肥胖症的患者的影响，结果令人瞩目。经过 48 周的治疗，患者平均减少了 20.5% 的总脂肪质量，同时增加了 3.6% 的瘦体重，显著减少了腰围，总体体重减轻了 6.5%，还改善了血糖水平。在治疗组和安慰剂组之间，出现副作用的比率以及副作用的强度相当相似。</p>
</div><p>Lilly's study of bimagrumab is expected to wrap up in mid-2025. If the results agree with the other trial's, the business will doubtlessly want to advance the program into phase 3 studies and then commercialization, assuming regulators give it the green light.</p>
<div class="lb-trans"><p>预计礼来对 bimagrumab 的研究将于 2025 年中期结束。如果结果与其他试验一致，该公司无疑将希望将该项目推进到第 3 期研究，然后进行商业化，假设监管机构批准。</p>
</div><p>If it is eventually approved for sale, it will probably not struggle to gain market share, even in the face of determined opposition. A weight loss medicine that efficiently liquidates fat around the abdomen while slightly boosting muscle growth is an obvious winner, and so far there's nothing else on the market that can compare. And, when paired with Lilly's extensive efforts to make other souped-up anti-obesity medicines, its stock could see a significant catalyst if the phase 2 results look favorable, so it's one more reason to buy the stock now.</p>
<div class="lb-trans"><p>如果最终获得销售批准，它可能不会在面对坚决反对的情况下难以获得市场份额。一种有效清除腹部脂肪并略微促进肌肉生长的减肥药物显然是一种赢家，到目前为止市场上没有其他产品可以媲美。而且，当与礼来大力努力研发其他强化抗肥胖药物的努力相结合时，如果第 2 期结果看起来令人满意，其股价可能会迎来重大推动，这是现在购买该股票的另一个理由。</p>
</div><h2>2. BioAge Labs</h2>
<div class="lb-trans"><h2>2. BioAge Labs</h2>
</div><p><strong>BioAge Labs</strong>(BIOA 4.94%) is still working on launching its first drug, but its lead candidate could offer a highly compelling set of advantages over today's crop of weight loss drugs. That program, called azelaprag, could also potentially help patients to lose weight while preserving or perhaps even augmenting their lean muscle mass.</p>
<div class="lb-trans"><p><strong>BioAge Labs</strong>（BIOA 4.94%）仍在努力推出其首个药物，但其主力候选药物可能比当今的减肥药物具有一系列引人注目的优势。该项目名为 azelaprag，也可能帮助患者减肥的同时保留甚至增加其瘦肌肉质量。</p>
</div><p>At the moment, azelaprag is in phase 2 clinical trials testing it as a combination with the blockbuster weight loss drugs produced by both Eli Lilly and Novo Nordisk. The results from its phase 1b clinical trial are promising.</p>
<div class="lb-trans"><p>目前，azelaprag 正处于第 2 期临床试验阶段，正在测试与礼来和诺和诺德生产的拳头减肥药物的联合使用。其第 1b 期临床试验的结果令人鼓舞。</p>
</div><p>In a 10-day study of 21 seniors confined to bed rest -- as in, the patients weren't allowed to leave their bed for more than a week -- only one of the 11 patients in the treatment group experienced a decline in their muscle quality, compared to eight out of the 10 in the placebo group. Their muscles also retained their dimensions significantly better than the patients who were administered the placebo. In particular, their thigh circumference measurement was two times as, on average.</p>
<div class="lb-trans"><p>在一项对 21 名长期卧床的老年人进行的为期 10 天的研究中，只有治疗组中的 11 名患者中有 1 名患者的肌肉质量下降，而安慰剂组中有 10 名患者中有 8 名患者的肌肉质量下降。他们的肌肉尺寸也比接受安慰剂的患者明显保持得更好。特别是，他们的大腿围尺寸平均增加了两倍。</p>
</div><p>In fact, some of the patients getting azelaprag actually saw some of their muscle dimensions increase a small amount. Pre-clinical data from animal models also suggest that the candidate has a potent weight loss effect via prompting a slew of favorable metabolic changes, but those findings will need to be replicated in humans before they're worth getting excited about.</p>
<div class="lb-trans"><p>事实上，一些接受 azelaprag 的患者实际上看到其部分肌肉尺寸略微增加。动物模型的临床前数据还表明，该候选药物通过促使一系列有利的代谢变化具有强大的减肥效果，但这些发现需要在人类中得到复制后才值得激动。</p>
</div><p>BioAge claims that azelaprag is capable of these impressive accomplishments because it leads to physiological effects that overlap the effects of physical exercise. If that's true, barring any major safety signals and assuming that the remaining clinical trials go as planned, it's easy to see how it could be working on a home-run drug here. It's worth buying the stock on the basis of that potential, as long as you keep your exposure small for now, and as long as you're comfortable with investing in a highly risky pre-revenue biotech stock.</p>
<div class="lb-trans"><p>BioAge 声称 azelaprag 能够取得这些令人印象深刻的成就，因为它导致的生理效应与体育锻炼的效应重叠。如果这是真的，除非出现重大安全信号，并且假设剩余的临床试验按计划进行，很容易看出它可能正在研发一种成功的药物。基于这一潜力，购买该股票是值得的，只要您目前保持小额投资，并且愿意投资于一个风险极高的未盈利生物技术股票。</p>
</div><p>But don't let this biotech's long road to revenue be too discouraging. On Oct. 1, it closed its initial public offering (IPO) and a concurrent private placement of its shares, raising gross proceeds of more than $238 million. Its trailing-12-month operating expenses were just $51.5 million, so it has at least a couple of years before it'll need to raise more cash, even when considering the higher costs of running mid- and late-stage clinical trials in the near future.</p>
<div class="lb-trans"><p>但不要让这家生物技术公司漫长的盈利之路使您感到过于沮丧。10 月 1 日，它结束了首次公开发行（IPO）和同时进行的私募股份发行，筹集了超过 2.38 亿美元的总收入。其过去 12 个月的运营费用仅为 5150 万美元，因此即使考虑到不久的将来运行中后期和晚期临床试验的更高成本，它至少还有几年时间不需要筹集更多资金。</p>
</div>

两只值得现在购买的下一代减肥股票